Literature DB >> 30048045

Risk factors and strategies in nonadherence with subcutaneous immunotherapy: a real-life study.

Yongshi Yang1, Yin Wang1, Lin Yang1, Jingru Wang1, Nan Huang1, Xiaolong Wang1, Lintao Hu1, Qing Jiang1, Guanghui Liu1, Rongfei Zhu1.   

Abstract

BACKGROUND: Allergen immunotherapy (AIT) is still the only causal treatment for allergic diseases. However, conventional subcutaneous immunotherapy (SCIT) administration schedules are time-consuming and patient nonadherence is a major barrier to achieving a satisfactory therapeutic effect. Our study aimed to analyze the causes leading to discontinuation of SCIT and to determine risk factors associated with nonadherence in respiratory allergies.
METHODS: This was a prospective study. Patients with respiratory allergies who had received standardized dust mite SCIT were enrolled from January 2012 to January 2014. And a follow-up study on these subjects was conducted via telephone interviews on an interval of 3 months and online communication through social network applications. Reasons for discontinuation were documented when patients claimed to stop treatment.
RESULTS: A total of 311 patients were enrolled in the study. The adherence rate at year 3 was 64.6%. Fifty-nine patients (19.0%) dropped out in year 1, 31 (10.0%) in year 2, and 20 (6.4%) in year 3. Reasons for nonadherence included inconvenience (32.7%), ineffectiveness (25.5%), improvement of symptoms (22.7%), and adverse reactions (14.5%). Children had higher adherence than adults (70.7% vs 55.0%) (p < 0.05). The dropout reasons were different among the children and adults groups (p < 0.005). The follow-up work was carefully and thoroughly done. All the 311 (100%) patients accepted the telephone interview, and 296 (95.2%) patients submitted questions and got rapid replies from doctors online.
CONCLUSION: Adherence to SCIT was less than satisfactory in the real-life study. A close communication between doctors and patients is helpful in enhancing adherence with AIT in clinical practice.
© 2018 ARS-AAOA, LLC.

Entities:  

Keywords:  adherence; allergic rhinitis; asthma; real life; subcutaneous immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 30048045     DOI: 10.1002/alr.22190

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  4 in total

1.  Subcutaneous Allergen Immunotherapy in Children: Real Life Compliance and Effect of COVID-19 Pandemic on Compliance.

Authors:  Elif Soyak Aytekin; Özge Soyer; Bülent E Şekerel; Ümit M Şahiner
Journal:  Int Arch Allergy Immunol       Date:  2021-04-22       Impact factor: 2.749

2.  Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19.

Authors:  Merve Erkoç; Betül Özdel Öztürk; Dilşad Mungan; Derya Öztuna; Sevim Bavbek; Yavuz Selim Demirel; Ömür Aydın; Betül Ayşe Sin
Journal:  Asia Pac Allergy       Date:  2022-01-24

3.  Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic.

Authors:  Ilkay Koca Kalkan; Hale Ates; Kurtulus Aksu; Selma Yesilkaya; Musa Topel; Dilek Cuhadar Ercelebi; Suleyman Turkyilmaz; Ali Oncul; Senay Demir
Journal:  World Allergy Organ J       Date:  2021-06-08       Impact factor: 4.084

4.  Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study.

Authors:  Cristiano Caruso; Barbara Bramé; Diego Bagnasco; Alessia Cocconcelli; Valeria Ortolani; Valerio Pravettoni; Sergio Scarpa; Giuliana Zisa; Giovanni Passalacqua; Stefania Colantuono
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.